Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric guselkumab long-term extension study
2023-509560-16-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of guselkumab in Crohn's disease, autoimmune colitis and juvenile psoriatic arthritis (JPsA), sponsored by Janssen Pharmaceutical. Planned start Oct 2024; status: authorised.
02
Drugs
guselkumab
03
Conditions
Crohn's diseaseautoimmune colitisjuvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on 2023-509560-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509560-16-00.